U.S. markets closed
  • S&P Futures

    3,233.25
    +2.00 (+0.06%)
     
  • Dow Futures

    26,707.00
    +22.00 (+0.08%)
     
  • Nasdaq Futures

    10,828.00
    -1.00 (-0.01%)
     
  • Russell 2000 Futures

    1,452.90
    +6.20 (+0.43%)
     
  • Crude Oil

    39.54
    -0.39 (-0.98%)
     
  • Gold

    1,865.30
    -3.10 (-0.17%)
     
  • Silver

    22.44
    -0.66 (-2.88%)
     
  • EUR/USD

    1.1667
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    0.6760
    +0.0120 (+1.81%)
     
  • Vix

    28.58
    +1.72 (+6.40%)
     
  • GBP/USD

    1.2719
    -0.0006 (-0.05%)
     
  • USD/JPY

    105.4180
    +0.0860 (+0.08%)
     
  • BTC-USD

    10,319.94
    +70.47 (+0.69%)
     
  • CMC Crypto 200

    208.89
    -5.08 (-2.37%)
     
  • FTSE 100

    5,899.26
    +69.80 (+1.20%)
     
  • Nikkei 225

    23,214.87
    -131.62 (-0.56%)
     

Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020 at 2:00 p.m. Eastern time.

This conference is virtual and a live webcast of the presentation can be accessed through the investor relations section of the Company’s website at www.clovisoncology.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days.

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado; please visit www.clovisoncology.com for more information, including additional office locations in the U.S. and Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005980/en/

Contacts

Anna Sussman
303.625.5022
asussman@clovisoncology.com

Breanna Burkart
303.625.5023
bburkart@clovisoncology.com